Olix Pharmaceuticals, Inc.

Sungkyunkwan University

Korea Institute of Science and Technology

Oncotag Diagnostics Co., Ltd.

Dong Ki Lee

Sun Woo Hong

Tae Yeon Lee

Ji Hyun Kim

Woong Hee Lee

Byoung Koun Min

Hanna Lee

Yun Jeong Hwang

Ung Lee

Dayeon Yu

Ji Eom

Dua Pooja

Sae-Lo-Oom Lee

Young-Dong Kim

Yu Ran Na

Sunghoon Kim

Hyun Joo Lee

Yang Hee Kim

Hyung Suk Oh

Nam Hoon Kwon

Isu Hong

Jihye Hwang

Hyung-Suk Oh

Heesung Eum

Dahye Won

Seojung Han

Seokhyeon Cheong

Da Hye Won

Sung Ill Jang

Jai Hyun Koh

Beom Jin Lim

Sae Lo Oom Lee

Da Seul Son

Chan Il Chang

Sung Iii Jang

Provided are a basic electrocatalyst applied to a carbon dioxide reduction and ethylene production system, a basic electrocatalyst electrode and an apparatus each including the same, and a method of manufacturing the basic electrocatalyst electrode. The basic electrocatalyst electrode for for carbon dioxide reduction and ethylene production includes: catalyst particles each including copper hydroxide (Cu(OH)); and a basic compound. Since the basic electrocatalyst electrode has high carbon dioxide reduction performance and high ethylene selectivity, the basic electrocatalyst electrode may be applied to a reduction electrode of a carbon dioxide reduction and ethylene production apparatus and may exhibit high current density and high ethylene selectivity. The basic electrocatalyst electrode may be manufactured by a simple method, and may be applied to a large-area electrode.

Basic electrocatalyst for carbon dioxide reduction and ethylene production, electrode and apparatus each including the same, and method of manufacturing the electrode

Provided is a device for removing nitrogen oxide, the device including an inflow path for gas containing nitrogen oxide; and a reversible metal complex compound coming into contact with the gas containing nitrogen oxide which is introduced through the inflow path, wherein the reversible metal complex compound includes a central metal ion reacting and binding with nitrogen oxide; and a ligand coordinating with the central metal ion, wherein when the central metal ion is oxidized, the bound nitrogen oxide is separated, and the oxidized central metal ion is reduced to recombine with nitrogen oxide.

Method of and device for removing nitrogen oxide in gas

The present technology relates, in part, to long double-stranded RNA (dsRNA) (e.g., 30 or more base pairs) that inhibits gene expression.

Long double-stranded RNA for RNA interference

Proposed is an iridium alloy catalyst having reversible catalytic activity for an oxygen evolution reaction (OER), a hydrogen evolution reaction (HER), and a hydrogen oxidation reaction (HOR) by including an iridium alloy including iridium (Ir) and nickel (Ni). The iridium alloy catalyst according to the present disclosure is rapidly converted to an iridium alloy catalyst in an oxide form and an iridium alloy catalyst in a metallic form according to applied voltage by controlling its crystallinity. Thus, even in case an oxide layer is formed after the OER, the oxidation layer disappears during the HER and HOR and the properties of an iridium metal catalyst remain, thereby maintaining HER/HOR performance.

Iridium alloy catalyst having reversible catalytic activity and preparation method thereof

The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.

Method for diagnosis of bile duct cancer using methionyl-tRNA synthetase in bile duct cell

In various aspects and embodiments, the invention provides compounds or agents that potentiate siRNA cellular entry or activity, and provides methods for identifying such compounds or agents. Exemplary agents that act as L-type calcium channel blockers are described herein, and are shown to potentiate gene silencing with cp-asiRNAs.

Pharmaceutical compositions and methods for potentiating gene silencing

The present invention relates to an RNAi-inducing nucleic acid molecule having a new structure and the use thereof, and more particularly to a novel nucleic acid molecule having a structure comprising a first strand, which is 24-121 nt in length and comprises a region complementary to a target nucleic acid, and a second strand which is 13-21 nt in length and has a region that binds complementarily to the region of the first strand, which is complementary to the target nucleic acid, so that the nucleic acid molecule inhibits the expression of a target gene with increased efficiency, and to a method of inhibiting the expression of a target gene using the nucleic acid molecule. The nucleic acid molecule structure of the present invention increases the efficiency with which the nucleic acid molecule inhibits the target gene. Alternatively, the nucleic acid molecule of the present invention can either increase the ability of the siRNA to bind to the target gene or cause synergistic cleavage, by introduction of antisense DNA, antisense RNA, ribozyme or DNAzyme, thereby increasing the efficiency with which the nucleic acid molecule inhibits the target gene. In addition, when the nucleic acid molecule according to the present invention is used, the efficiency with which the target gene is inhibited can be maintained for an extended period of time. Accordingly, the RNAi-inducing nucleic acid molecule of the present invention can be effectively used for the treatment of cancer or viral infection in place of conventional siRNA molecules.

Nucleic acid molecules inducing RNA interference, and uses thereof

In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit CTGF expression and are therefore useful for treating idiopathic pulmonary fibrosis.

Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor

In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.

Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB

In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit IL4R&#x3b1;, TRPA1, and/or F2RL1 expression and are therefore useful for treating atopic dermatitis or asthma.

Treatment of atopic dermatitis and asthma using RNA complexes that target IL4R&#x3b1;, TRPA1, or F2RL1

In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3

The present invention relates to a novel siRNA structure and the use thereof, and more particularly to a double-stranded siRNA molecule comprising an antisense strand and a sense strand, wherein the siRNA molecule has at least one single nucleotide bulge formed by introducing a single nucleotide into the antisense strand, particularly at position 2 from the 5' end, and to a method of using the same to silence a target gene. The siRNA molecule of the invention shows high target gene silencing efficiency while minimizing off-target effects caused by the antisense strand, and thus has improved target selectivity. Accordingly, the siRNA molecule of the invention can be substituted for conventional siRNA molecules and can be widely be used in siRNA-based gene silencing techniques, including gene therapy.

SiRNA structure for minimizing off-target effects caused by antisense strands, and use thereof

Growing community of inventors

Seoul, South Korea

Dong Ki Lee